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Centella asiatica (CA), commonly named gotu kola, is an Ayurvedic herb used to enhance memory and nerve function. To inves-
tigate the potential use of CA in Alzheimer’s disease (AD), we examined the eﬀects of a water extract of CA (GKW) in the Tg2576
mouse,amurinemodelofADwithhighβ-amyloidburden.OrallyadministeredGKWattenuatedβ-amyloid-associatedbehavioral
abnormalities in these mice. In vitro, GKW protected SH-SY5Y cells and MC65 human neuroblastoma cells from toxicity induced
by exogenously added and endogenously generated β-amyloid, respectively. GKW prevented intracellular β-amyloid aggregate for-
mationinMC65cells.GKWdidnotshowanticholinesteraseactivityorprotectneuronsfromoxidativedamageandglutamatetoxi-
city, mechanisms of current AD therapies. GKW is rich in phenolic compounds and does not contain asiatic acid, a known CA
neuroprotective triterpene. CA thus oﬀers a unique therapeutic mechanism and novel active compounds of potential relevance to
the treatment of AD.
1.Introduction
Centella asiatica (L.) Urban, family Apiaceae (CA), is known
as Mandookaparni or Brahmi in Ayurvedic medicine. It is
highly regarded as a “rasayana” or rejuvenating herb [1]a n d
isreputedtoincreaseintelligenceandmemory[1].Thedried
herb has enjoyed growing popularity in the USA and other
Western countries, where it is sold as the dietary supplement
“gotu kola” [2].
Cognitive eﬀects of the aqueous extract of CA (100–
300mg/kg/day) have been evaluated in several rodent studies
using standard tests including shuttle box, step-through
paradigm, elevated plus maze, and passive avoidance tests.
CA extract markedly improved learning and memory of
wild-type rats [3], rats subjected to CNS toxicity (intrac-
erebroventricularstreptozotocin)[4],andpentylenetetrazole
(PTZ) kindled rats [5]. When administered to neonatal mice
from day 15 to 30 postpartum, the extract caused signiﬁcant
enhancement in learning eﬃciency and spatial memory with
no eﬀects on locomotor function [6]. Direct neurotropic
eﬀects of CA have also been reported. CA aqueous extract
caused signiﬁcant increases in dendritic arborization of api-
cal and basal dendrites in hippocampal neurons of neonatal
mice [6]a n db o t ha d u l t[ 7] and neonatal [8] rats. These
studies, performed in diverse settings, show that CA water
extract has biological eﬀects of relevance to memory, learn-
ing, and aging, and potentially to disease progression in
Alzheimer’s disease (AD).
Thepresentstudyexaminestheeﬀectofawaterextractof
CA on behavioral deﬁcits in the Tg2576 transgenic mouse,
a murine model of AD. The Tg2576 or “Hsiao” transgenic
mouse has been described in detail [9, 10] and is one of the
most widely used animal models of AD. A mutant human
amyloid precursor protein (APP) gene inserted into the
genome gives rise to age-dependent hippocampal and
cortical β-amyloid (Aβ) plaques similar to AD pathology.2 International Journal of Alzheimer’s Disease
Plaques are not histologically evident until 10–12 months of
age, and plaque pathology is conﬁned to the hippocampus
and cerebral cortex. In other words, the age and region
dependence of pathology in AD are nicely recapitulated in
this strain. Other features of AD reproduced in this strain
are astrocytic and microglial activation surrounding the Aβ
plaques and dystrophic changes in neurites in the vicinity of
plaques [11]. Importantly, these mice display abnormalities
in standard behavioral tests. Open-ﬁeld behavior has been
shown to distinguish Tg2576 from wild-type mice, with
Tg2576 mice more active in the open ﬁeld than their wild-
type littermates [12]. Hippocampal dysfunction, resulting
in impaired spatial memory, is evident in the Morris water
maze and has been repeatedly shown to distinguish aged, Aβ
plaque-bearing Tg2576 from wild-type mice [9, 13]. These
behavioral tests were utilized in the present study.
In addition to in vivo studies, the present work examined
possible mechanisms underlying CA eﬀects in the Tg2576
mouse, using in vitro models. The mechanisms examined in-
clude cholinesterase inhibition and neuroprotectant eﬀects
against oxidative damage, glutamate toxicity, and beta amy-
loid toxicity. The ingredient compounds in CA aqueous ex-
tract were also investigated.
2.MaterialsandMethods
2.1.AqueousExtractionofCA. DriedCAwaspurchasedfrom
Oregon’s Wild Harvest, Sandy, OR (Batch no. GOT-10072C-
OGA). The identity of the herb was veriﬁed by means of
visual examination and by comparing its thin layer chro-
matographic proﬁle with that reported in the literature [14].
A dried water extract (GKW) was prepared by reﬂuxing CA
(120g) with water (1.5L) for 2hr, ﬁltering to remove plant
debris and freeze-drying to yield a residue (11.5g).
2.2. Chemical Analysis of CA Extracts. Water and ethanolic
extracts of CA were compared by high-performance liquid
chromatography coupled to UV detection (LC-UV) and
mass spectrometry (LC-MS). The extracts were chromato-
graphed alongside commercial reference standards of asi-
atic acid, madecassic acid, asiaticoside, and madecassoside
(ChromaDex,Irvine,CA).AnalysiswasperformedusingLC-
MS in negative ion mode on an LCQ Advantage ion trap
mass spectrometer (Thermo Electron, San Jose, CA) with an
in-line Surveyor autosampler and HPLC (Thermo Electron)
coupled to a Surveyor Photodiode array detector (Thermo
Electron). HPLC used an Aquasil 5μm C18 150 × 2.1mm
column eluting with a gradient of acetonitrile in water both
with 0.01% formic acid (acetonitrile 5% to 25% in 20min,
to 40% at 35min, 60% at 40min, 75% at 45min and then
returning to starting conditions).
2.3. Administration of GKW to Mice. Fifteen Tg2576 and 20
wild-type 20-month-old female mice were committed
to this experiment. Approximately half of each genotype
group was administered GKW in the drinking water at
a dose of 2mg/mL of water, with water bottles changed
every other day, calculated to yield 200mg/kg/day, a dose
previously shown to improve memory in wild-type rats [3].
The GKW-treated group included 8 Tg2576 and 10 wild-
type mice; the untreated group included 7 Tg2576 and 10
wild-type mice. Treatment was continued for 2 weeks, the
duration of treatment in published reports showing beha-
vioral eﬀects in wild-type animals [3]. Open-ﬁeld behavior
a n dM o r r i sw a t e rm a z et e s t i n gw e r ep e r f o r m e da tt h ee n do f
this period.
2.4. Open-Field Testing of Mice. Mice were placed in the cen-
ter of a square arena (38 × 38 × 64cm high) constructed of
whiteacrylonitrilebutadienestyrenefortwo5-minuteopen-
ﬁeld sessions on each of three consecutive days. Distance
moved and velocity ofeachmouse werecontinuously tracked
with a digital camera and “ANY-maze” software (ANY-Maze,
Inc., Greensburg, PA). After a 5-minute epoch was recorded,
the mouse was returned to the cage for 5 minutes and then
retested. For each mouse, two tests were conducted on each
of 3 days.
2.5. Morris Water Maze Testing of Mice. A subset of the
treated animals (5 untreated wild-type, 5 GKW-treated
Tg2576, and 5 untreated Tg2576) was also tested in the Mor-
ris water maze, a well established assay of hippocampal
spatial memory [15]. This paradigm tests the animal ability
tolearnandrememberthespatiallocationofaplatformsub-
merged 1cm in a 109cm circular pool of opaque water. The
mice were habituated to the examination room and holding
cages for two days and then received two days of “nonspatial
training” before commencement of hidden platform testing.
Each nonspatial training trial comprised placing the mouse
on the submerged platform for 60sec and then placing the
mouse in close proximity (within 2-3cm) to the platform
and allowing it to climb onto the platform from the water.
Training on the hidden platform water maze task began
24hr after the last habituation trial. At this stage, curtains
were opened to permit the mice visual access to extra maze
cues in the room surrounding the maze. Hidden platform
training was conducted over 16 trials on 4 consecutive days
(4 trials/day). The platform remains in a ﬁxed position
throughout hidden platform training. During a given trial,
the mouse is introduced into the pool at one of four ran-
domlychosenstartpoints(N,S,W,andE)andallowed60sec
to ﬁnd the platform. All trials were monitored by a video
camera positioned above the pool and the behavior of each
mousewasacquiredbyacomputerizedvideotrackingsystem
(ANY-Mazesoftware).Dependentmeasuresacquiredineach
trialincludetheescapelatency(i.e.,timetoﬁndtheplatform,
in sec), the cumulative distance (in cm) of the mouse from
the platform, and swim speed (in cm/sec). No mice in this
group needed to be excluded based on diﬃculty in swim-
ming, in climbing onto the platform, or exhibiting abnormal
swimming patterns or persistent ﬂoating.
2.6. Brain Levels of Soluble and Insoluble Aβ. Brain levels of
Aβ were measured in experimental mice at the conclusion of
behavioral testing described above. Tg2576 mice were sacri-
ﬁced and brains rapidly harvested, divided, and frozen until
analysis. Cortical tissue was then homogenized in buﬀered
saline and protease inhibitors and ultracentrifuged to yieldInternational Journal of Alzheimer’s Disease 3
a“ s o l u b l e ”f r a c t i o n ,a sw eh a v er e p o r t e dp r e v i o u s l y[ 16–
18]. The remaining pellet was rehomogenized and incubated
in guanidine and buﬀer and subsequently ultracentrifuged
to yield a “ﬁbrillar” fraction. Concentrations of Aβ1−40 and
Aβ1−42 were determined in each supernatant using com-
mercial ELISA kits, which distinguish the two isoforms
(BioSource international, Camarillo, CA). Total protein in
each fraction was determined by the Bradford method.
2.7. Neurotoxicity Induced by Extracellular Aβ. SHSY5Y neu-
roblastoma cells were grown in DMEM/F12 medium (from
Gibco) containing fetal calf serum (FCS; 10%), streptomycin
sulphate (100μg/mL), and penicillin G (1000U/mL) in a hu-
midiﬁed air/5% CO2 chamber at 37◦C. On day 1, the cells
were plated in 24-well plates (100,000 cells/well).
On day 4, cells were washed with FCS-free medium and
further incubated in FCS-free DMEM/F12 containing neu-
roblastoma growth supplement N-2 (1%; Gibco). GKW (0–
200μg/mL) was added and incubated overnight. On day 5,
cells were exposed to Aβ25−35 (American Peptide Company)
at 20 or 50μM for 48hrs in the presence of GKW. For this
assay, ﬁbrillar Aβ solution was freshly prepared by sonicating
as o l u t i o no fA β25−35 in medium for 1 minute prior to addi-
tion to cell cultures. On day 7, the supernatant was harvested
for LDH cell integrity assay; LDH release is a marker of cell
damage [19]. Fresh medium was added and cell number
assessed using CellTiter-Blue reagent (resazurin, Promega),
incubating for 2 hours and reading ﬂuorescence at 560nm
excitation and 590nm emission.
2.8. Intracellular Aβ-Induced Neurotoxicity in MC65 Cells.
MC65 cells are an established neuroblastoma cell line that
conditionally express the C-terminal fragment of amyloid
precursor protein (APP CTF) [20]. Following withdrawal of
tetracycline from the media, the cells generate endogenous
Aβ and die within 3 days. Expression of APP CTF in
MC65 cells leads to the formation of intracellular Aβ aggre-
gates. Previous studies have shown a strong correlation bet-
ween these aggregates and subsequent cytotoxicity that is
associated with oxidative stress [21] .M C 6 5c e l l sw e r ec u l -
tured and maintained in MEMEα supplemented with 10%
FBS (Gibco-BRL, Carlsbad, CA) and 1μg/mL tetracycline
(Sigma-Aldrich, St. Louis, MO) as previously described [21,
22]. Conﬂuent cells were trypsinized, washed with PBS,
resuspended in OptiMEM without phenol red (Gibco/BRL,
Carlsbad, CA), and plated at 25,000 cells/well in 48-well
plates in fresh medium containing vehicle or desired con-
centrations of GKW, in the absence of tetracycline. Cell via-
bility was measured at 2.75 days using the CellTiter 96
Aqueous Non-Radioactive Cell Proliferation Assay (Promega
Corporation, Madison, WI) according to manufacturer’s
instructions. Experiments were carried out in triplicate wells
for each condition and repeated 1-2 times.
2.9.APPCTFAggregationinMC65Cells. Cellswereplatedin
culturedisheswithouttetracyclineinthepresenceorabsence
of100μg/mLGKW.Cellswereharvestedat2daysandlysates
prepared by sonication and heating in Laemmli sample
buﬀer. Samples were reduced then separated on tricine gels,
transferred, and western blotted using mouse monoclonal
antibody 6E10 that recognizes Aβ1−17.
2.10. Aβ-Induced Nitric Oxide in Macrophages. RAW 264.7
cells were cultured in complete phenol red-free DMEM con-
taining 50 units/mL of penicillin, 50mg/mL of streptomycin,
44mM sodium bicarbonate, and 10% fetal bovine serum
(completemedium)at37◦Cin humidiﬁed air containing 5%
CO2. Cells were plated in 24-well plates (approximately 1 ×
105 cells/well)andculturedfor2daysuntil cellsreached80%
conﬂuency. Cells were washed, treated with fresh complete
mediacontainingvariousconcentrationsofGKWfor1hour,
and then induced with LPS (100ng/mL) or Aβ1−42 (20μM)
for an additional 24 hours. Aβ ﬁbril formation was induced
by incubating Aβ at 37◦C overnight prior to addition to
cell cultures. Nitrite was determined in supernatants from
treated macrophages using Griess reagent as described previ-
ously [23, 24]. Nitrite concentrations were determined using
dilutions of sodium nitrite in complete medium as a stan-
dard.
2.11. Anticholinesterase Activity. Cholinesterase activity was
measured by the method of Ellman et al. [25], which is
based on the formation of a yellow reaction product when
thiocholine is liberated from acetylthiocholine and combines
with the test reagent, dithiobisnitrobenzoic acid (DTNB).
Potential cholinesterase inhibitory eﬀect of GKW was tested
directly in an assay using mouse plasma cholinesterase.
DTNB buﬀer (80μL) was added to a 96-well plate, followed
by mouse plasma (5μL), and then test agent (5μL), consist-
ing of GKW solution (2.5, 25, and 250μg/mL), neostigmine
(2.5μg/mL; positive control), or buﬀer (negative control)
and the solution was warmed to 37◦C. The substrate, acetyl-
thiocholine, was then added and absorbance recorded at
450nm for 5 minutes.
2.12. Glutamate-Induced Neurotoxicity. Potential protection
against glutamate-induced toxicity was examined in cortical
neurons obtained from neonatal Sprague-Dawley rats. On
day 1, cells were plated (200,000 cells per well) in 48-well
plates using neurobasal medium supplemented with B27
(2%) containing antioxidants, 2mM L-glutamine (Gibco).
On day 4, the cells were treated with Ara-C (5μM) to remove
glial cells. On day 7, cells were washed with prewarmed
CSF buﬀer (2x, 0.5mL/well) then incubated with neurobasal
medium, plus L-glutamine (2mM) and B27 (2%) minus
antioxidants, overnight. On day 8, sodium glutamate (0–
1000μM)withorwithoutGKW(0–200μg/mL)wasaddedto
the medium and the cells incubated overnight. On day 9,
fresh medium was added and cell number evaluated using
CellTiter Blue reagent (resazurin, Promega), incubating for
2 hours and reading ﬂuorescence in a ﬂuorimeter at 560nm
excitation and 590nm emission.
2.13. Antioxidant Activity. Potential antioxidant eﬀects of
GKW were assessed in vitro in SH-SY5Y cells treated with
hydrogen peroxide as an oxidative stressor. SHSY5Y neu-
roblastoma cells were grown in DMEM/F12 medium (from
Gibco) containing fetal calf serum (FCS; 10%), streptomy-
cin sulphate (100μg/mL), and penicillin G (1000U/mL) in4 International Journal of Alzheimer’s Disease
a humidiﬁed air/5% CO2 chamber at 37◦C. On day 1, the
cellswereplatedin24-wellplates(100,000cells/well).Onday
4, medium was replenished with fresh medium containing
NGF (10ng/mL). After 24 hours (day 5), GKW (0, 50, 100,
and200μg/mL)wasaddedandthecellsincubatedovernight.
On day 6, medium containing GKW was replaced with fresh
medium containing less FCS (2%) and NGF (10ng/mL).
Cells were treated with a range of concentrations of H2O2
(0–500μM) for 2-3 hours. Medium containing peroxide was
removedandcellsincubatedovernightinfreshmediumcon-
taining FCS (2%) and NGF (10ng/mL). On day 7, super-
natant was harvested for lactate dehydrogenase (LDH) cell
integrity assay (102). Fresh medium was added and cell
number evaluated using CellTiter Blue reagent (resazurin,
Promega), incubating for 2 hours and reading ﬂuorescence
at 560nm excitation and 590nm emission.
3. Results andDiscussion
The water extractable compounds (GKW) represented ap-
proximately 10% of the dry weight of CA herb. There was no
diﬀerence in water consumption between control animals
and animals receiving water containing GKW.
Open-ﬁeld testing (Figure 1) showed that GKW treat-
ment caused an improvement in behavioral abnormalities
seeninTg2576mice.Wild-typemice,bothGKWtreatedand
untreated, were less active on the second trial of each day,
presumably due to habituation. Untreated Tg2576 mice, in
contrast, failed to habituate to the surroundings. However,
GKW-treated Tg2576 mice explored in a manner similar to
wild-type mice, with their data overlapping the two wild-
type groups (P = 0.02 for diﬀerence between untreated and
GKW-treated Tg2576 mice by ANOVA). “Normalization” of
open-ﬁeld behavior in Tg2576 mice has also been reported
with an intervention that suppresses soluble Aβ levels [12].
In the Morris water maze paradigm (Figure 2), GKW
treatment improved the impaired learning ability evident in
Tg2576 mice. Wild-type animals exhibit a “learning curve”
requiring less time and less distance to ﬁnd the hidden
platform with repeated trials, while untreated Tg2576 mice
require equivalent time and distance despite repeated expo-
sures. In contrast, the GKW-treated Tg2576 mice learn in a
manner similar to the wild-type animals, with latency and
distancetraveledtoﬁndtheplatformdecliningwithrepeated
exposures. On day 4, time to ﬁnd the platform was signiﬁ-
cantly greater for untreated Tg2576 mice than for wild-type
(P = 0.002) or GKW-treated Tg2576 mice (P = 0.004).
Distance traveled to ﬁnd the platform was also signiﬁcantly
greater on day 4 for untreated Tg2576 mice compared to
wild-type (P = 0.006) or GKW-treated Tg2576 mice (P =
0.003). There was no signiﬁcant diﬀerence between groups
in the “visible platform” control for sensorimotor function
(data not shown).
SincetreatmentwithGKWamelioratedaspatialmemory
impairment in Tg2576 mice, which is speciﬁcally associated
with the appearance of Aβ plaques, without producing any
change in wild-type mouse memory, it would appear that
the observed eﬀect of GKW is speciﬁc to Aβ.H o w e v e r ,
Figure 3 shows that there were no signiﬁcant diﬀerences
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Figure 1: Open-ﬁeld assay: eﬀect of GKW on total distance trav-
elled. Wild-type mice, both treated (triangle) and untreated (ﬁlled
diamond),arelessactiveonthesecondtrialofeachday,presumably
due to habituation. Untreated Tg2576 mice (open diamond), in
contrast, fail to habituate to the surroundings. GKW-treated Tg25-
76mice(circles)exploreinamannersimilartowild-typemice,with
their data overlapping the two wild-type groups. From statistical
analysis (ANOVA), P = 0.02 for diﬀerence between untreated (n =
7) and GKW-treated (n = 8) Tg2576 mice; error bars omitted for
clarity.
between levels of any of the forms of Aβ in treated and un-
treated Tg2576 mice. This is in contrast to results obtained
in PSAPP mice, a model for Alzheimer’s disease (AD) where
mice express both amyloid precursor protein and presenilin
1 mutations, in the long term (8 months). In these mice,
administration of CA extract displayed in vitro antioxidant
eﬀects and also reduced beta amyloid plaque burden [26].
The PSAPP mice develop amyloid plaque pathology at an
earlier age than Tg2576 [27], permitting more rapid com-
pletionofantiamyloidexperiments.However,lossoftheage-
and region-dependence of pathology diminishes the ﬁdelity
of this strain to some extent. Since GKW treatment attenu-
atedtheneurologicconsequencesofabnormalAβ deposition
in Tg 2576 mice without changing Aβ levels per se, the ability
of GKW to modulate the toxic eﬀects of Aβ were pursued
in vitro, with an emphasis on mechanisms which are either
independent of or “downstream” from Aβ.
In preliminary experiments, GKW showed a moder-
a t ep r o t e c t i v ee ﬀect against toxicity due to exogenously
added Aβ in SH-SY5Y human neuroblastoma cells in vitro
(Figure 4(a)). Lactate dehydrogenase (LDH) release from
these cells, which is inversely related to cell viability, was
reduced in the presence of GKW (Figure 4(b)). The eﬀect
of GKW on toxicity due to endogenously generated Aβ was
investigated in MC65 human neuroblastoma cells. GKW
added to the cell culture medium prevented MC65 cell
deathfollowingtetracyclinewithdrawal,inadose-dependent
manner (Figure 5). Evidence from Western blots indicated
that GKW may prevent the aggregation of Aβ in these cells.International Journal of Alzheimer’s Disease 5
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Figure 2: GKW eﬀects in the Morris water maze. Mean ± SEM of (a) escape latency and (b) distance traveled to ﬁnd platform is shown for
each day of testing. Wild-type animals exhibit a “learning curve” requiring less time and less distance to ﬁnd the hidden platform with
repeated trials, while untreated Tg2576 mice require equivalent time and distance despite repeated exposures. In contrast, the GKW-treated
mice learn in a manner similar to the wild-type animals, with latency and distance traveled to ﬁnd the platform declining with repeated
exposures. On day 4, time to ﬁnd the platform was signiﬁcantly greater for untreated Tg2576 mice than for wild-type (P = 0.002) or GKW-
treated Tg2576 mice (P = 0.004). Distance traveled to ﬁnd the platform was also signiﬁcantly greater on day 4 for untreated Tg2576 mice
compared to wild-type (P = 0.006) or GKW-treated Tg2576 mice (P = 0.003).
In a related study (data not shown), GKW inhibited Aβ-
induced nitric oxide (NO) production in the RAW 264.7
macrophage cell line. Interestingly, GKW inhibited NO
production induced by Aβ but did not inﬂuence LPS-
induced NO levels in these cells. Taken together, these data
indicated that components in GKW are able to modulate the
toxic eﬀects of Aβ.
Other potential mechanisms by which GKW may have
improved cognitive function in the Tg2576 mice were also
investigated but yielded negative results. No direct inhibitory
eﬀect of GKW (2.5 to 250μg/mL) on cholinesterase activ-
ity in vitro was observed, whereas robust inhibition was
observed using the positive control neostigmine. Eﬀects of
GKW on glutamate toxicity to rat cortical neurons were
investigated. GKW (100 or 200μg/mL) was not directly toxic
to rat cortical neurons nor did it protect the cells from toxi-
city induced by 250 and 1000μM glutamate (cell viability
30% and 25% of control, resp.). To examine potential anti-
oxidanteﬀectsofGKW,SHSY5Yneuronalcellswereexposed
to H2O2,whichshoweddose-dependenttoxicitytoSH-SY5Y
cells over the range 125–500μM. GKW (50–200μg/mL),
while not toxic to the cells, did not protect against toxicity at
any of the peroxide concentrations tested. Thus, GKW does
not appear to possess antioxidant eﬀects.
Five drugs are currently FDA-approved for the symp-
tomatic treatment of AD, targeting mechanisms of unclear
relationship to the primary neurodegenerative process. The
ﬁrst four drugs (tacrine, donepezil, rivastigmine, and galan-
tamine)areacetylcholinesteraseinhibitors,whichactbyaug-
menting cholinergic neurotransmission [28]. Each of these
drugs has shown improved cognitive outcomes in treated
AD patients compared to placebo-treated subjects, and the
eﬃcacy across drugs makes the case that cholinesterase
inhibitionisaviabletreatmentstrategyforAD[28].Theﬁfth
and most recent antidementia drug to receive FDA appro-
val is memantine. Memantine is a noncholinergic drug, act-
ing instead at the NMDA class of glutamate receptor. In ad-
dition to showing clinical eﬃcacy in human subjects with
AD [29, 30], memantine has also been shown to improve
cognition in murine models of cerebral amyloidosis. NMDA
antagonism should therefore be considered among the pos-
sible mechanisms of action of treatments producing cogni-
tive improvement in murine models of AD. Our in vitro
experimentsshowednoevidencethatCAactsbywayofthese
established therapeutic targets since there was no eﬀect on
cholinesterase activity or glutamate neurotoxicity.
In addition to the established therapies just described,
strategies aimed at preventing the accumulation of, or pro-
moting the clearance of, Aβ are under study. Inhibitors of
amyloid synthesis and immunization against Aβ have dimin-
ished brain pathology and yielded cognitive and behavioral
improvements in murine models of AD. Although amyloid
synthesis inhibitors such as Lilly semagacestat have yielded
negative clinical results [31], antiamyloid immunotherapy6 International Journal of Alzheimer’s Disease
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Figure 3: Soluble and insoluble Aβ in cortical tissue from treated
and untreated mice. Mean values ± SEM are shown. Treated and
untreated Tg2576 mice did not diﬀer signiﬁcantly in levels of any of
the measured isoforms of Aβ.
(bapineuzumab) remains under development with some
promising initial results [32]. “Antiamyloid” strategies,
therefore, represent another potential mechanism of cog-
nition-enhancing therapies in AD. Our results do not show
an eﬀect of CA on Aβ levels per se but suggest that CA may
protect neurons from Aβ-induced neurotoxicity without
actually changing brain levels of Aβ. Most current clinical
trialsarefocusedonsuppressionofAβ levels,thustheneuro-
protectant eﬀect of CA described here represents a novel
mechanism,potentiallycomplementarytothedrugsindeve-
lopment.
CA may also be a source of a novel chemical class for the
treatment of AD. HPLC analysis of GKW revealed a complex
mixture of substances (Figure 6). This did not include asiatic
acid or madecassic acid, well-known triterpene components
of CA [33, 34], which were, however, extractable from the
same plant material using ethanol (Figure 6). The absence
of asiatic acid in GKW is notable since asiatic acid has been
previously associated with neuroprotective and neurotropic
eﬀects [35–38]. However, an aqueous extract lacking asiatic
acid produced robust behavioral eﬀects in this study. Table 1
lists the spectral characteristics of the major peaks found
in GKW using LC-UV and LC-MS. UV spectra with
maxima over 300nm are indicative of a highly conjugated
system, characteristic of ﬂavonoids. CA is reported to be a
rich source of quercetin [39]. Flavonoids isolated to date in
CA include 3-glucosylkaempferol, 3-glucosylquercetin and
diosmin [40, 41]. The molecular weights listed in Table 1 did
not correspond to any of these 3 compounds, nor any other
compounds isolated hitherto from CA (online chemical
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Figure4:(a)GKWat100and200μg/mLshowsamodestprotective
eﬀect on SH-SY5Y cells from Aβ toxicity (beta amyloid 25–35) in
vitro. The% oflive cells is decreased ontreatment with Aβ,a ne ﬀect
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database, SciFinder). These ﬁndings imply the presence of
potentially novel neuroactive ingredients in GKW which are
yet to be fully characterized.
Compared to the wealth of animal data described earlier,
there have been fewer studies on cognitive eﬀects of CA in
humans. In one study, 30 mentally retarded children aged 7–
18 years showed improvement in their general abilities after
receiving 500mg daily of dried CA herb for 3 months [42]. A
more recent study [43] showed that an extract of CA (250–
750mg daily for 2 months) improved cognitive performance
in healthy, elderly volunteers. In a placebo-controlled study,
administration of CA herb (0.5g/kg body weight) to healthy,
middle-aged volunteers for 2 months resulted in improve-
ments in several tests of cognitive function [44]. A study in
elderly subjects with mild cognitive impairment found im-
provements in their cognitive test results, including the
mini mental state examination, following administration of
500mg dried CA twice a day for a 6-month period [45].
The traditional use of CA as an enhancer of cognitive
function is therefore well supported by in vitro, in vivo,a n d
small-scale human studies conducted so far. The ultimateInternational Journal of Alzheimer’s Disease 7
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Figure 6:HPLCcomparisonofCAwaterandethanolextractsmadefromthesamebatchofplantmaterial.Asiaticacid(AA)andmadecassic
acid (MA) are detected in the ethanolic extract, but not in the water extract (GKW). The water extract GKW contains mostly very polar
compounds as shown by their earlier elution than the triterpenes AA and MA. HPLC was conducted on an Aquasil 150mm × 2.1mmC18
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returning to starting conditions, detector wavelength 205nm. AA and MA were identiﬁed by comparison of retention times to those of com-
mercial standards.
goal of these studies is to develop evidence for the clinical use
of CA, or compounds derived from CA, in the treatment or
prevention of AD. The combination of data from in vitro and
animal studies in the present work supports the impression
that CA has the potential for clinical beneﬁt in AD by way
of a novel mechanism of action. Well-designed, controlled
clinical trials of CA in AD and other forms of cognitive
impairment are clearly warranted. The characterization of
the active components of CA and elucidation of their mech-
anism of action would support these clinical studies.8 International Journal of Alzheimer’s Disease
Table 1:MolecularweightandUVdataobtainedforGKWcomponentsusingLC-MSandLC-UV.ReversedphasegradientHPLCchromato-
graphy with UV and negative ion mass spectral detection was performed as described in Section 2.
Retention time Most abundant ions (m/z); (Mol Wt−1) UV λ max (nm) Possible structure, based on
ﬂavonoid handbook [46]
12.33 399, 353 215, 325 Prenylated ﬂavone
16.57 531 215, 265, 310 Malonyl, butyryl, or diacetyl ﬂavone glycoside
21.05 477 205, 255, 355 Glycosyl or glucuronyl methylated ﬂavones
22.64 561, 515 215, 325 Diglycosyl ﬂavonoid or a catechin
25.21 601 215, 325 No matches found
33.49 577 220, 295, 320 Diglycosyl ﬂavonoid or a proanthocyanidin
4. Conclusions
A water extract of CA (GKW) attenuated Aβ-associated
behavioral abnormalities in the Tg2576 mouse, a murine
model of AD. In vitro, GKW protected SH-SY5Y cells and
MC65 human neuroblastoma cells from toxicity induced by
exogenously added and endogenously generated Aβ,r e s p e c -
tively. GKW did not show anticholinesterase activity or pro-
tect neurons from oxidative damage and glutamate toxicity,
mechanisms of current AD therapies. The combination of
data from in vitro and animal studies in the present work
supports the CA potential for conferring clinical beneﬁt in
AD, possibly by way of a novel mechanism of action. GKW
does not contain asiatic acid, a known CA neuroprotective
triterpene,butisrichinphenoliccompounds.CAmaythere-
fore contain novel active compounds of relevance to the
treatment of AD.
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